|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 366.21 USD | -0.43% |
|
-0.90% | +11.88% |
| 12:39pm | Facing the Wall of Worry |  |
| 14/03 | GSK and Amgen to add medicines to TrumpRx, Fox Business reports | RE |
| Capitalization | 20TCr 17TCr 16TCr 15TCr 27TCr 18,25900Cr 28TCr 1,86200Cr 74TCr 8,72300Cr 74TCr 73TCr 31,50800Cr | P/E ratio 2026 * |
24.6x | P/E ratio 2027 * | 22.7x |
|---|---|---|---|---|---|
| Enterprise value | 24TCr 21TCr 19TCr 18TCr 33TCr 21,91700Cr 34TCr 2,23600Cr 89TCr 10,47100Cr 89TCr 87TCr 37,82000Cr | EV / Sales 2026 * |
6.26x | EV / Sales 2027 * | 5.95x |
| Free-Float |
99.85% | Yield 2026 * |
2.74% | Yield 2027 * | 2.93% |
Last Transcript: Amgen Inc.
| 1 day | -0.43% | ||
| 1 week | -0.90% | ||
| Current month | -5.65% | ||
| 1 month | -0.81% | ||
| 3 months | +12.57% | ||
| 6 months | +33.46% | ||
| Current year | +11.88% |
| 1 week | 365.93 |  | 380.14 |
| 1 month | 361.4 | | 391.29 |
| Current year | 318.21 | | 391.29 |
| 1 year | 261.43 | | 391.29 |
| 3 years | 211.71 | | 391.29 |
| 5 years | 198.64 | | 391.29 |
| 10 years | 133.64 | | 391.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 01/05/2012 |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 01/01/2020 |
Esteban Santos
COO | Chief Operating Officer | 59 | 25/07/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 01/01/2013 |
Tyler Jacks
BRD | Director/Board Member | 65 | 01/01/2012 |
Robert Eckert
BRD | Director/Board Member | 71 | 01/01/2012 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -1.11% | 5.08% | 136 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.43% | -0.90% | +16.74% | +55.90% | 20TCr | |
| +0.80% | -0.53% | +21.09% | +198.99% | 88TCr | |
| -0.21% | +0.47% | +48.34% | +56.48% | 58TCr | |
| -2.52% | -4.53% | +3.74% | +42.59% | 39TCr | |
| -0.31% | -3.85% | +2.73% | +22.31% | 32TCr | |
| -0.63% | -0.91% | +20.21% | +32.52% | 30TCr | |
| -0.37% | -3.45% | +22.70% | +57.14% | 29TCr | |
| -0.26% | -0.16% | +22.25% | +7.41% | 29TCr | |
| -0.15% | +0.74% | +30.11% | +82.03% | 18TCr | |
| +0.82% | -2.53% | -54.50% | -49.02% | 17TCr | |
| Average | -0.33% | -1.36% | +13.34% | +50.64% | 35.94TCr | |
| Weighted average by Cap. | -0.24% | -1.32% | +18.80% | +77.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.78TCr 3.31TCr 2.99TCr 2.86TCr 5.2TCr 3,50000Cr 5.41TCr 36TCr 14TCr 1,67200Cr 14TCr 14TCr 6,04000Cr | 3.87TCr 3.39TCr 3.06TCr 2.93TCr 5.32TCr 3,58200Cr 5.53TCr 37TCr 14TCr 1,71100Cr 15TCr 14TCr 6,18200Cr |
| Net income | 804.51Cr 703.23Cr 635.32Cr 607.76Cr 1.11TCr 74TCr 1.15TCr 7.59TCr 3.01TCr 36TCr 3.02TCr 2.96TCr 1,28400Cr | 873.64Cr 763.65Cr 689.92Cr 659.98Cr 1.2TCr 81TCr 1.25TCr 8.24TCr 3.27TCr 39TCr 3.28TCr 3.21TCr 1,39400Cr |
| Net Debt | 3.96TCr 3.46TCr 3.12TCr 2.99TCr 5.43TCr 3,65800Cr 5.65TCr 37TCr 15TCr 1,74800Cr 15TCr 15TCr 6,31300Cr | 3.3TCr 2.88TCr 2.6TCr 2.49TCr 4.53TCr 3,04800Cr 4.71TCr 31TCr 12TCr 1,45600Cr 12TCr 12TCr 5,26000Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/26/13 | 366.21 $ | -0.43% | 15,00,319 |
| 12/26/12 | 367.79 $ | -2.61% | 19,90,663 |
| 11/26/11 | 377.64 $ | +0.59% | 23,00,019 |
| 10/26/10 | 375.43 $ | -0.41% | 22,84,548 |
| 09/26/09 | 376.97 $ | +2.01% | 27,20,112 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AMGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition